November 28, 2011; Hyderabad, India: GVK Biosciences (GVK BIO), Asia’s leading drug discovery
research & development organization, announced today that it has entered into a drug discovery
alliance with the Moulder Center for Drug Discovery Research at Temple University.
As part of the multi-year integrated drug discovery collaboration, GVK BIO will be responsible for the
target validation, lead identification and lead optimization of small molecules in selected therapeutic
areas, including cardiovascular, metabolic, and central nervous system disorders.
The Moulder Center is a unique, fully integrated state-of-the-art drug discovery center that is used for
both internal research within Temple University and for external collaborations with pharmaceutical and
biotech companies and other universities. As part of the collaboration, GVK BIO will apply their
integrated drug discovery expertise and technologies to identify interesting small molecules against
selected targets. GVK Biosciences will be responsible for reagent generation, assay development and
establishing the screening cascade leading to lead identification and optimization. Moulder Center and
GVK BIO will be jointly responsible for designing the molecules for this program. The molecules will be
optimized and progressed through lead optimization to a pre-clinical candidate.
“Utilizing GVK BIO’s discovery chemistry and biology capabilities, we look forward to working with the
Moulder Center for Drug Discovery Research. Dr. Magid Abou-Gharbia, is a world renowned researcher
with more than 26 years of research experience and we are pleased to be working with him. This
collaboration with Temple University is among several academic collaborations GVK BIO has with
leading research institutions. ” said Manni Kantipudi, Chief Executive Officer, GVK Biosciences.
“This business model reflects the increasing trend of collaborations between academic centers of
excellence and pharmaceutical companies to discover new drugs.” said Dr. Magid Abou-Gharbia,
Director of the Moulder Center for Drug Discovery Research and Associate Dean for Research in
Temple’s School of Pharmacy “We are delighted to be working with GVK BIO’s experienced research
and discovery team to further leverage both teams’ talents to identify innovative drug candidates”.
About GVK Biosciences
GVK Biosciences (GVK BIO) is Asia’s leading Discovery Research and Development organization. GVK BIO
provides a broad spectrum of services, stand-alone and integrated, across the R&D value chain. Our discovery services consist of Chemistry, Biology and Informatics; the development services include
Clinical Research, Clinical Pharmacology and Process R&D. GVK BIO’s diverse portfolio of more than 150
customers includes some of the world’s largest pharmaceutical, biotechnology, agro, life-sciences
companies and leading academic institutions. Please visit us at www.gvkbio.com to know more.
About the Moulder Center for Drug Discovery Research
The Moulder Center for Drug Discovery Research was established in Temple University’s School of
Pharmacy in 2008. The newly-founded research center has already received over $10 Million in funding
from private donations, federal grants, contract research, and a recent Temple University Drug
Discovery Research Initiative. Led by its director, Dr. Magid Abou-Gharbia, the Moulder Center is a fully
integrated drug discovery facility. The Center now has seven laboratories, including state-of-the-art
medicinal chemistry and parallel synthesis facilities, screening laboratories, as well as new equipment
and a 40,000-compound library that will allow for better drug screening and optimization. The Center
also has pharmacokinetic / bioanalytical capabilities plus computer-aided drug design (CADD) for virtual
drug screening. Three additional laboratories in molecular pharmacology and medicinal chemistry are
also under construction. The Center is located in Philadelphia, Pa., a region that has historically been
the home to so many of the pharmaceutical companies that it has become the heart of pharma or
biomedical research, and has earned the moniker, “Silicon Valley of biomedical research and drug
discovery.” The center's research capabilities are enhanced through its numerous internal and external
collaborations and partnerships.
For any further information, please contact:
Dy General Manager – Corporate Communications
GVK Biosciences Private Limited
T 0044 743 8307768